-
Something wrong with this record ?
The effects of atorvastatin treatment on the mean platelet volume and red cell distribution width in patients with dyslipoproteinemia and comparison with plasma atherogenicity indicators--A pilot study
M. Kucera, D. Balaz, P. Kruzliak, R. Ciccocioppo, S. Oravec, L. Rodrigo, A. Zulli, E. Hirnerova, P. Sabaka, A. Komornikova, J. Sabo, P. Slezak, L. Gaspar,
Language English Country United States
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Anticholesteremic Agents therapeutic use MeSH
- Apolipoprotein A-I blood MeSH
- Apolipoprotein B-100 blood MeSH
- Atherosclerosis blood MeSH
- Atorvastatin therapeutic use MeSH
- Dyslipidemias blood drug therapy MeSH
- Erythrocyte Indices drug effects MeSH
- Middle Aged MeSH
- Humans MeSH
- Pilot Projects MeSH
- Aged MeSH
- Mean Platelet Volume * MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
OBJECTIVES: The mean platelet volume (MPV) and red cell distribution width (RDW) have recently arisen interest because of their association with an increased cardiovascular risk. The aim of our study was, therefore, to determine whether an association exists between MPV, RDW and lipoprotein sub-fractions, and to show the impact of statin therapy on these new possible biomarkers of atherosclerotic risk. DESIGN AND METHODS: A cohort of 40 patients with hypercholesterolaemia (29 females, mean age 62.9±9 years), without previous hypolipidaemic treatment were enrolled. The patients were treated with atorvastatin 40 mg/day for 12 weeks. Total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density cholesterol (HDL-C), triglycerides (TG), LDL-C sub-fractions [large LDL-C 1-2 and small dense (sd)-LDL-C 3-7], apolipoproteins (apoA1, apoB), apoB/apoA1 ratio, atherogenic index of plasma (AIP), haematological parameters (including MPV, RDW) and safety parameters (renal, hepatic) were measured before and after 12 weeks of atorvastatin treatment. RESULTS: At baseline, a strong correlation between HDL-C, TG, sd-LDL-C, apoB, apoB/apoA1, and AIP with MPV (r=-0.55, p<0.001; r=0.57, p<0.001; r=0.73, p<0.001; r=0.41, p<0.05; r=0.52, p<0.001; r=0.61, p<0.001, respectively) and RDW (r=-0.49, p<0.001; r=0.62, p<0.001; r=0.67, p<0.001; r=0.41, p<0.05; r=0.43, p<0.05; r=0.65, p<0.001, respectively) was found. After 12 weeks of treatment with atorvastatin, MPV and RDW values underwent significant modification only in those patients displaying the strongest lipid-lowering effect. CONCLUSIONS: Values of MPV and RDW seem to reflect a pro-atherogenic lipoprotein profile mainly represented by the presence of sd-LDL-C.
Central University Hospital of Asturias Oviedo Asturias Spain
Clinica Medica 1 Fondazione IRCCS Policlinico San Matteo Università degli Studi di Pavia Italy
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16010510
- 003
- CZ-PrNML
- 005
- 20160413093449.0
- 007
- ta
- 008
- 160408s2015 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.clinbiochem.2015.02.010 $2 doi
- 024 7_
- $a 10.1016/j.clinbiochem.2015.02.010 $2 doi
- 035 __
- $a (PubMed)25727667
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kucera, Marek $u 2nd Department of Internal Medicine, Comenius University and University Hospital, Bratislava, Slovak Republic.
- 245 14
- $a The effects of atorvastatin treatment on the mean platelet volume and red cell distribution width in patients with dyslipoproteinemia and comparison with plasma atherogenicity indicators--A pilot study / $c M. Kucera, D. Balaz, P. Kruzliak, R. Ciccocioppo, S. Oravec, L. Rodrigo, A. Zulli, E. Hirnerova, P. Sabaka, A. Komornikova, J. Sabo, P. Slezak, L. Gaspar,
- 520 9_
- $a OBJECTIVES: The mean platelet volume (MPV) and red cell distribution width (RDW) have recently arisen interest because of their association with an increased cardiovascular risk. The aim of our study was, therefore, to determine whether an association exists between MPV, RDW and lipoprotein sub-fractions, and to show the impact of statin therapy on these new possible biomarkers of atherosclerotic risk. DESIGN AND METHODS: A cohort of 40 patients with hypercholesterolaemia (29 females, mean age 62.9±9 years), without previous hypolipidaemic treatment were enrolled. The patients were treated with atorvastatin 40 mg/day for 12 weeks. Total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density cholesterol (HDL-C), triglycerides (TG), LDL-C sub-fractions [large LDL-C 1-2 and small dense (sd)-LDL-C 3-7], apolipoproteins (apoA1, apoB), apoB/apoA1 ratio, atherogenic index of plasma (AIP), haematological parameters (including MPV, RDW) and safety parameters (renal, hepatic) were measured before and after 12 weeks of atorvastatin treatment. RESULTS: At baseline, a strong correlation between HDL-C, TG, sd-LDL-C, apoB, apoB/apoA1, and AIP with MPV (r=-0.55, p<0.001; r=0.57, p<0.001; r=0.73, p<0.001; r=0.41, p<0.05; r=0.52, p<0.001; r=0.61, p<0.001, respectively) and RDW (r=-0.49, p<0.001; r=0.62, p<0.001; r=0.67, p<0.001; r=0.41, p<0.05; r=0.43, p<0.05; r=0.65, p<0.001, respectively) was found. After 12 weeks of treatment with atorvastatin, MPV and RDW values underwent significant modification only in those patients displaying the strongest lipid-lowering effect. CONCLUSIONS: Values of MPV and RDW seem to reflect a pro-atherogenic lipoprotein profile mainly represented by the presence of sd-LDL-C.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a anticholesteremika $x terapeutické užití $7 D000924
- 650 _2
- $a apolipoprotein A-I $x krev $7 D016632
- 650 _2
- $a apolipoprotein B-100 $x krev $7 D053299
- 650 _2
- $a ateroskleróza $x krev $7 D050197
- 650 _2
- $a atorvastatin $x terapeutické užití $7 D000069059
- 650 _2
- $a dyslipidemie $x krev $x farmakoterapie $7 D050171
- 650 _2
- $a erytrocytární znaky $x účinky léků $7 D004909
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a střední objem trombocytu $7 D063847
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a pilotní projekty $7 D010865
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Balaz, David $u 2nd Department of Internal Medicine, Comenius University and University Hospital, Bratislava, Slovak Republic.
- 700 1_
- $a Kruzliak, Peter $u Department of Cardiovascular Diseases, International Clinical Research Centre, St. Anne's University Hospital and Masaryk University, Brno, Czech Republic; Department of Medical Physics and Biophysics, Faculty of Medicine, Pavol Jozef Safarik University, Kosice, Slovak Republic. Electronic address: peter.kruzliak@savba.sk.
- 700 1_
- $a Ciccocioppo, Rachele $u Clinica Medica I, Fondazione IRCCS Policlinico San Matteo, Università degli Studi di Pavia, Italy.
- 700 1_
- $a Oravec, Stanislav $u 2nd Department of Internal Medicine, Comenius University and University Hospital, Bratislava, Slovak Republic.
- 700 1_
- $a Rodrigo, Luis $u Central University Hospital of Asturias (HUCA), Oviedo, Asturias, Spain.
- 700 1_
- $a Zulli, Anthony $u The Centre for Chronic Disease Prevention & Management (CCDPM), Western CHRE, Victoria University, St Albans, Australia.
- 700 1_
- $a Hirnerova, Eva $u 2nd Department of Internal Medicine, Comenius University and University Hospital, Bratislava, Slovak Republic.
- 700 1_
- $a Sabaka, Peter $u 2nd Department of Internal Medicine, Comenius University and University Hospital, Bratislava, Slovak Republic.
- 700 1_
- $a Komornikova, Andrea $u 2nd Department of Internal Medicine, Comenius University and University Hospital, Bratislava, Slovak Republic.
- 700 1_
- $a Sabo, Jan $u Central University Hospital of Asturias (HUCA), Oviedo, Asturias, Spain.
- 700 1_
- $a Slezak, Peter $u Department of Simulation and Virtual Medical Education, Comenius University, Bratislava, Slovak Republic.
- 700 1_
- $a Gaspar, Ludovit $u 2nd Department of Internal Medicine, Comenius University and University Hospital, Bratislava, Slovak Republic. Electronic address: ludovitgaspar@gmail.com.
- 773 0_
- $w MED00001119 $t Clinical biochemistry $x 1873-2933 $g Roč. 48, č. 9 (2015), s. 557-61
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25727667 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160408 $b ABA008
- 991 __
- $a 20160413093533 $b ABA008
- 999 __
- $a ok $b bmc $g 1113939 $s 934878
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 48 $c 9 $d 557-61 $e 20150226 $i 1873-2933 $m Clinical biochemistry $n Clin Biochem $x MED00001119
- LZP __
- $a Pubmed-20160408
